Short Interest in RemeGen Co., Ltd. (OTCMKTS:REGMF) Declines By 42.3%

RemeGen Co., Ltd. (OTCMKTS:REGMF) was the recipient of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 196,500 shares, a decline of 42.3% from the February 28th total of 340,500 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days.

RemeGen Stock Performance

REGMF opened at $1.50 on Monday. The company’s 50-day moving average price is $1.50 and its 200 day moving average price is $1.51. RemeGen has a fifty-two week low of $1.50 and a fifty-two week high of $4.00.

About RemeGen

RemeGen Co, Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers.